For patients with advanced, radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) harboring specific genetic alterations such as RET mutations, conventional therapies yield suboptimal outcomes. This evidence concerns the gene RET and differentiated thyroid carcinoma.